

CONFERENCE PROGRAM

MONDAY, APRIL 26, 2010

08:00 – 08:30

Opening Session

Ballroom

OPENING REMARKS AND GREETINGS

M. Bialer, Organizing Committee, Israel

GREETINGS

R.H. Levy, Organizing Committee, USA

E. Perucca, Organizing Committee & ILAE Treasurer, Italy

08:30 – 13:30

Session I

Ballroom

**LEARNING FROM THE PAST: LESSONS LEARNT AFTER 18
YEARS OF EILAT CONFERENCES**

Chairpersons: **R. Katz**, USA
E. Perucca, Italy

08:30 HOW STRATEGIES FOR DRUG DISCOVERY HAVE CHANGED
H.S. White, USA

08:50 Discussion

09:00 WHAT HAVE WE LEARNT ABOUT PREDICTING EFFICACY AND
SAFETY
B. Schmidt, Germany

09:20 Discussion

09:30 HOW HAVE TRIAL DESIGNS EVOLVED
J.A. French, USA

09:50 Discussion

MONDAY, APRIL 26, 2010 (continued)

08:30 – 13:30	Session I (cont.)	Ballroom
10:00	HOW HAVE REGULATORY REQUIREMENTS CHANGED R. Katz, USA	
10:20	Discussion	
10:30	<i>Coffee</i>	
11:00	HOW INDUSTRY CHANGED IN ITS INTEREST OR APPROACH TO DEVELOPING NEW AEDs • J. Isojärvi, USA • R. Twyman, USA	
11:20	Discussion	
11:30	HAVE THE AEDs INTRODUCED SINCE EILAT I (1992) MADE A DIFFERENCE FOR EFFICACY? E. Perucca, Italy	
11:50	Discussion	
12:00	HAVE THE AEDs INTRODUCED SINCE EILAT I (1992) MADE A DIFFERENCE FOR SAFETY? T. Tomson, Sweden	
12:20	Discussion	
12:30	WHAT DOES IT TAKE TO GET A NEW AED APPROVED? General Discussion Moderators: R. Twyman, USA H.S. White, USA	
14:00	<i>Meet in lobby of Royal Beach hotel for walk to Boat Tour</i>	

TUESDAY, APRIL 27, 2010

08:00 – 10:00

Session II-A

Ballroom

DRUGS IN DEVELOPMENT

Chairs: **M. Bialer**, Israel
R.H. Levy, USA

08:00 BRIVARACETAM (ucb 34714)
S. Lu, *UCB Inc*, USA

08:20 Discussion

08:30 CARISBAMATE (RWJ-333369)
G.P. Novak, *Johnson & Johnson Pharmaceutical Research & Development*, USA

08:50 Discussion

09:00 2-DEOXY-(D)-GLUCOSE
Presented by **T.P. Sutula**, University of Wisconsin, USA

09:20 Discussion

09:30 GANAXOLONE
Presented by **V. Nohria**, Mercer University, USA
on behalf of *Marinus Pharmaceuticals*, USA

09:50 Discussion

10:00 *Coffee*

TUESDAY, APRIL 27, 2010 (cont.)

10:30 – 12:30

Session II-B

Ballroom

DRUGS IN DEVELOPMENT

Chairs: **E. Perucca**, Italy
H.S. White, USA

- 10:30 HUPERZINE A
Presented by **S.C. Schachter**, Harvard Medical School,
USA
- 10:50 Discussion
- 11:00 ICA-105665
Icagen, Inc, USA
Presented by **D. Kasteleijn-Nolst Trenité**, La Sapienza University,
Italy
- 11:20 Discussion
- 11:30 NAX 5055
B.D. Klein *NeuroAdjuvants*, USA
- 11:50 Discussion
- 12:00 PERAMPANEL (E2007)
A. Laurenza, Eisai Inc, USA
- 12:20 Discussion
- 12:30 *Lunch*

TUESDAY, APRIL 27, 2010 (cont.)

13:30 – 16:00

Session II-C

Ballroom

DRUGS IN DEVELOPMENT

Chairs: **S.I. Johannessen**, Norway
H.J. Kupferberg, USA

- 13:30 RETIGABINE
GlaxoSmithKline, UK and Valeant Pharmaceuticals International, USA
Presented by **J.M.J. Hammond**, Valeant Pharmaceuticals International, USA
- 13:50 Discussion
- 14:00 T-2000 and T-2007
A. Yacobi, Taro Pharmaceuticals, USA
- 14:20 Discussion
- 14:30 *Coffee*
- 15:00 VALPROIC ACID – 2nd GENERATION
Presented by **M. Bialer**, The Hebrew University of Jerusalem, Israel
- 15:20 Discussion
- 15:30 YKP3089
S.J. Lee, SK Life Science, USA
- 15:50 Discussion

WEDNESDAY, APRIL 28, 2010

08:00 – 10:00

Session III - A

Ballroom

**PROGRESS REPORT ON SECOND-GENERATION
TREATMENTS**

Chairs: **B. Schmidt**, Germany
T. Tomson, Sweden

- 08:00 CLOBAZAM
S.M Sagar, *Lundbeck Inc.*, USA
- 08:20 Discussion
- 08:30 ESLICARBAZEPINE ACETATE – CLINICAL PHARMACOLOGY
BIAL-Portela & C., SA, Portugal
Presented by **E. Perucca**, University of Pavia, Italy
- 08:40 ESLICARBAZEPINE ACETATE – CLINICAL TRIALS
BIAL-Portela & C., SA, Portugal
Presented by **E. Ben Menachem**, University of Gothenburg,
Sweden
- 08:50 Discussion
- 09:00 LACOSAMIDE
J. Isojarvi, *UCB S.A.*, USA
- 09:20 Discussion
- 09:30 LEVETIRACETAM
F. Tonner, *UCB S.A.* Belgium
- 09:50 Discussion
- 10:00 *Coffee*

WEDNESDAY, APRIL 28, 2010

10:30 – 12:30

Session III - B

Ballroom

**PROGRESS REPORT ON SECOND-GENERATION
TREATMENTS**

Chairs: **J. French**, USA
A.M. Kanner, USA

- 10:30 PREGABALIN
Pfizer, Inc., USA
Presented by **E. Perucca**, University of Pavia, Italy
- 10:50 Discussion
- 11:00 STIRIPENTOL – MECHANISMS OF ACTION
Biocodex, France
Presented by **J.L. Fisher**, University of South Carolina,
USA
- 11:20 Discussion
- 11:30 STIRIPENTOL – CLINICAL DATA
Biocodex, France
Presented by **C. Chiron**, Necker-Enfants Malades
Hospital, Paris, France
- 11:50 Discussion
- 12:00 TOPIRAMATE
L.M. Ford, *Johnson & Johnson Pharmaceutical Research &
Development*, USA
- 12:20 Discussion
- 12:30 *Lunch*

WEDNESDAY, APRIL 28, 2010

13:30 – 15:30

Session III - C

Ballroom

**PROGRESS REPORT ON SECOND-GENERATION
TREATMENTS**

Chairs: **S.C. Schachter**, USA
 H.S. White, USA

- 13:30 VIGABATRIN
 S.M. Sagar, *Lundbeck Inc.*, USA
- 13:50 Discussion
- 14:00 ZONISAMIDE
 R. van Maanen, *Eisai*, UK
- 14:20 Discussion
- 14:30 *Coffee*
- 15:00 OXCARBAZEPINE MODIFIED-RELEASE (MR)
 FORMULATION
 Desitin Arzneimittel GmbH, Germany
 Presented by **B.J. Steinhoff**, Epilepsy Center Kork,
 Germany
- 15:20 Discussion

THURSDAY, APRIL 29, 2010

08:30 – 10:30

Session IV-A

Ballroom

DETECTING, ASSESSING AND PREVENTING ADVERSE EFFECTS OF AEDs

Chairs: **S.I. Johannessen**, Norway
T. Tomson, Sweden

08:30 GENETIC PREDISPOSITION TO IDIOSYNCRATIC EFFECTS: IMPLICATIONS FOR PREVENTION
P. Kwan, Hong Kong

08:50 Discussion

09:00 SCREENING FOR ADVERSE AED EFFECTS: FROM RESEARCH TO APPLICATIONS IN ROUTINE PRACTICE
F. Gilliam, USA

09:20 Discussion

09:30 MINIMIZING ADVERSE CNS EFFECTS: RISK FACTORS AND IMPLICATIONS FOR DRUG SELECTION DOSING
- COGNITIVE EFFECTS, **G.A. Baker**, UK
- BEHAVIOURAL AND PSYCHIATRIC EFFECTS, **A.M. Kanner**, USA

09:50 Discussion

10:00 MECHANISMS OF DRUG ACTION AS PREDICTORS OF ADVERSE EFFECTS OF INDIVIDUAL AEDs AND AED COMBINATIONS
G.J. Sills, UK

10:20 Discussion

10:30 *Coffee*

THURSDAY, APRIL 29, 2010 (cont.)

11:00 – 12:30

Session IV-B

Ballroom

DETECTING, ASSESSING AND PREVENTING ADVERSE EFFECTS OF AEDs

Chairs: **S.I. Johannessen**, Norway
E. Perucca, Italy

- 11:00 METANALYSIS OF DATA FROM REGULATORY DRUG TRIALS TO EXPLORE TREATMENT-RELATED ADVERSE EFFECTS: RATIONALE AND LIMITATIONS
R. Katz, USA
- 11:20 Discussion
- 11:30 CONTRIBUTIONS OF TDM TO THE DEVELOPMENT OF SAFER AND MORE EFFECTIVE AED TREATMENT
D. Berry, UK
- 11:50 Discussion
- 12:00 DRUG PRESCRIPTION REGISTRIES: POSSIBILITIES AND LIMITATIONS IN DETECTING ADVERSE AED EFFECTS
P. Mattsson, Sweden
- 12:20 Discussion